Amgen said Tuesday that its experimental immune therapy dazodalibep improved systemic disease activity in a pivotal Phase 3 trial of adults with Sjögren’s disease, a chronic autoimmune condition for which the Food and Drug Administration has approved no disease-modifying medicine. The announcement is potentially important for patients with organ involvement and persistent systemic illness, but it is not yet a complete clinical result.

The company’s September 22 topline disclosure said the OASIZ 301 trial met its primary endpoint at 48 weeks, with a statistically significant and clinically meaningful improvement on the EULAR Sjögren’s Syndrome Disease Activity Index, or ESSDAI. Amgen also said a treatment difference was visible by week four and persisted through week 48.

Those claims cannot yet be independently assessed in detail. Amgen did not disclose the numerical change in ESSDAI for either group, the difference between dazodalibep and placebo, a confidence interval, a p-value, results for major secondary endpoints, or adverse-event rates by treatment arm. Reuters and MedCity News both noted that key data remain reserved for a future medical meeting. The result therefore supports further scrutiny, not a conclusion that the drug is ready for routine care.

A large, controlled trial in systemic disease

OASIZ 301 was a randomized, double-blind, placebo-controlled trial in adults with moderate-to-severe systemic Sjögren’s disease. The sponsor’s study record lists 651 participants and describes quadruple masking of participants, care providers, investigators and outcome assessors. Eligible participants had an ESSDAI score of at least five despite symptomatic or local therapy and had anti-Ro antibodies, rheumatoid factor or both.

That design is a meaningful strength. Randomization and masking reduce the risk that differences in patient characteristics, treatment expectations or outcome assessment explain the result. A placebo comparison is especially relevant in Sjögren’s research because symptoms and measured disease activity can fluctuate and placebo response has complicated earlier drug programs. Independent coverage from Fierce Biotech confirmed the trial’s 48-week comparison and emphasized that full numerical results have not been released.

ESSDAI is a physician-assessed composite covering disease activity across multiple organ systems. It is not simply a dryness score. A foundational validation study of ESSDAI and the patient-reported ESSPRI scale defined moderate activity as an ESSDAI score from five through 13 and high activity as 14 or higher; it also proposed a drop of at least three points as a minimum clinically important improvement. OASIZ 301 used a stricter secondary responder definition of a decrease of at least five points, according to Amgen.

That distinction matters. A statistically significant average change can be real while still leaving open how many patients experienced an improvement large enough to affect their lives or prevent organ damage. Until the company reports the group averages, responder rates, baseline severity and performance across organ domains, readers cannot determine the magnitude or consistency of the benefit.

Why Sjögren’s is difficult to treat and measure

Sjögren’s is often associated with dry eyes and dry mouth because the immune system damages moisture-producing glands. But the disease can also involve joints, nerves, lungs, kidneys, blood vessels and other organs. The Sjögren’s Foundation describes a heterogeneous illness that may include profound fatigue, chronic pain, neuropathy, major-organ involvement and an increased risk of lymphoma. It estimates that as many as four million Americans live with the condition and says nine in 10 diagnosed patients are women.

Heterogeneity is not a technical footnote. Patients with systemic organ activity may have different treatment priorities from those whose main burden is dryness, pain and fatigue. Clinician-scored activity and patient-reported symptoms also measure different parts of the disease. A multicenter validation study found that ESSDAI and ESSPRI were reliable but poorly correlated, supporting separate evaluation of systemic activity and symptoms.

Amgen designed parallel late-stage trials around that divide. OASIZ 301 focused on people with systemic disease activity. OASIZ 303, listed by the University of California, San Diego trial registry as a randomized, double-blind, placebo-controlled study of about 434 participants, enrolls people with substantial symptoms but low systemic activity. Its primary objective is to test patient-reported symptoms, and its estimated completion is December 2026. A positive OASIZ 301 result does not predict with certainty that the drug will improve dryness, fatigue or pain in that distinct group.

How the drug works and what earlier evidence showed

Dazodalibep is a fusion protein that blocks CD40 ligand, a signaling molecule involved in communication among T cells, B cells and antigen-presenting cells. By interrupting that pathway, the drug is intended to reduce immune activation rather than only relieve dryness or pain.

The biological case is supported by an earlier randomized Phase 2 trial published in Nature Medicine. In the systemic-disease cohort of 74 participants, the least-squares mean ESSDAI change at day 169 was minus 6.3 points with dazodalibep and minus 4.1 with placebo, a 2.2-point difference with a reported p-value of 0.0167. A second cohort of 109 people with high symptom burden and limited systemic involvement also met its patient-reported primary endpoint.

Those findings established a signal worth testing in larger studies, but they also illustrate why the Phase 3 numbers are essential. The placebo group improved substantially in Phase 2, and the between-group difference on ESSDAI was smaller than the change within the treated group. The Phase 3 trial is much larger and ran for 48 weeks, yet without its actual effect estimate it is impossible to know whether the earlier signal was replicated, strengthened or narrowed.

Safety remains only partly visible

Amgen said the most common events reported more often with dazodalibep than placebo were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions, generally described as mild or moderate. It said discontinuations caused by adverse events were infrequent and balanced between groups, with no imbalance in thromboembolic events or opportunistic infections.

That is reassuring as far as it goes, particularly because immune-modulating biologics can raise concerns about infections and other uncommon harms. But the release did not provide denominators, percentages, serious adverse-event counts, laboratory abnormalities or exposure-adjusted rates. It also cannot establish long-term safety. Amgen is conducting an open-label extension, while the 301 study record indicates safety follow-up through week 56.

The published Phase 2 study described dazodalibep as generally safe and well tolerated, with commonly reported events including COVID-19, diarrhea, headache, nasopharyngitis, upper respiratory infection, joint pain, constipation and urinary tract infection. Phase 2 trials, however, are too small to characterize rare risks reliably. A complete benefit-risk judgment requires the larger Phase 3 tables and longer follow-up.

What the result could change

If the full dataset confirms a meaningful systemic benefit with an acceptable safety profile, dazodalibep could move Sjögren’s care toward targeted treatment of the disease process rather than a patchwork of symptom management and off-label immune suppression. That could be especially relevant for patients with active disease beyond the eyes and mouth.

Several steps remain. The detailed OASIZ 301 results need scientific presentation and peer review. Regulators will examine the prespecified analysis, missing data, subgroup consistency, multiplicity controls, adverse events and whether the measured improvement is large enough to matter clinically. They may also consider the separate OASIZ 303 results and longer-term data when judging how broadly any indication should be written.

For patients and clinicians, the practical message is cautious optimism. The trial design and earlier randomized evidence make the announcement more credible than an uncontrolled observation, and success in a large Phase 3 study is an important milestone in a field with substantial unmet need. But dazodalibep remains investigational, is not FDA-approved, and should not be treated as proven therapy on the basis of a company summary. The next decisive evidence will be the actual numbers.